Clinical overview of promising nonthienopyridine antiplatelet agents

41Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Three novel nonthienopyridine antiplatelet agents-cangrelor, ticagrelor (AZD6140), and SCH 530348-are in advanced clinical testing in patients with coronary artery disease. Cangrelor and ticagrelor are direct and reversible inhibitors of the platelet adenosine 5′-diphosphate P2Y12 receptor, whereas SCH 530348 is a thrombin receptor antagonist. Clinical data available to date for each of these compounds suggest that they have safety and efficacy profiles that will be advantageous to patients with acute coronary syndromes or undergoing percutaneous intervention. We review the clinical features of these new platelet inhibition therapies. © 2008 Mosby, Inc. All rights reserved.

Cite

CITATION STYLE

APA

Angiolillo, D. J., & Guzman, L. A. (2008). Clinical overview of promising nonthienopyridine antiplatelet agents. American Heart Journal, 156(2 SUPPL.), 23S-28S. https://doi.org/10.1016/j.ahj.2008.06.006

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free